Sophie E Willis
6PUBLICATIONS
33CO-AUTHORS
Get your video featured.
Publish with JoVEGet your video featured.
Publish with JoVE
Publications (6)
Sort by Publication Date:
|Apr 03, 2026
Treatment monitoring by biomarker analysis in a Phase I dose-expansion study of AZD2811 for relapsed/refractory small-cell lung cancer.Melissa L Johnson, Giulia Fabbri, Carmela Ciardullo
|Mar 31, 2026
Phase 1 study of ceralasertib, an ATR kinase inhibitor, in combination with durvalumab in patients with recurrent or metastatic NSCLC or HNSCC.Juanita S Lopez, Kevin J Harrington, Seock-Ah Im
|Apr 29, 2023
Epitope Lability of Phosphorylated Biomarkers of the DNA Damage Response Pathway Results in Increased Vulnerability to Effects of Delayed or Incomplete Formalin Fixation.Elizabeth J Wiseman, Jennifer I Moss, James Atkinson
|Oct 19, 2021
Retrospective analysis of Schlafen11 (SLFN11) to predict the outcomes to therapies affecting the DNA damage response.Sophie E Willis, Claudia Winkler, Martine P Roudier
|Jun 02, 2021
Specific targeting of the KRAS mutational landscape in myeloma as a tool to unveil the elicited antitumor activity.Antonio Sacco, Cinzia Federico, Katia Todoerti
|Nov 09, 2019
AZD7648 is a potent and selective DNA-PK inhibitor that enhances radiation, chemotherapy and olaparib activity.Jacqueline H L Fok, Antonio Ramos-Montoya, Mercedes Vazquez-Chantada
Pageof 1
Frequent Collaborators
1 joint publications
Antonio Ramos-Montoya
1 joint publications
M Raymond V Finlay
1 joint publications
Stephanie Ling
1 joint publications
Elaine B Cadogan
1 joint publications
Federica Maccarinelli
1 joint publications
Vanessa Favasuli
1 joint publications
Alexey S Revenko
1 joint publications
Anna Staniszewska
1 joint publications
Chiara Cattaneo
1 joint publications
Roberto Ronca
